S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80
S&P 500   3,818.83
DOW   31,029.31
QQQ   283.80

Amphastar Pharmaceuticals Stock Forecast, Price & News

+0.90 (+2.71%)
(As of 06/29/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
331,829 shs
Average Volume
506,361 shs
Market Capitalization
$1.67 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock Forecast (MarketRank)

Overall MarketRank

2.46 out of 5 stars

Medical Sector

74th out of 1,432 stocks

Pharmaceutical Preparations Industry

26th out of 685 stocks

Analyst Opinion: 1.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 3.1 5 -4 -3 -2 -1 -
Amphastar Pharmaceuticals logo

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock News Headlines

Amphastar Pharmaceuticals (NASDAQ:AMPH) Trading 5.9% Higher
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
$62.12 million
Pretax Margin


Sales & Book Value

Annual Sales
$437.77 million
Cash Flow
$2.05 per share
Book Value
$9.31 per share


Free Float
Market Cap
$1.67 billion

Amphastar Pharmaceuticals Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Amphastar Pharmaceuticals' stock. Their AMPH stock forecasts range from $32.00 to $43.00. On average, they predict Amphastar Pharmaceuticals' stock price to reach $36.67 in the next twelve months. This suggests a possible upside of 7.4% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Amphastar Pharmaceuticals' stock performed in 2022?

Amphastar Pharmaceuticals' stock was trading at $23.29 on January 1st, 2022. Since then, AMPH shares have increased by 46.6% and is now trading at $34.15.
View the best growth stocks for 2022 here

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Amphastar Pharmaceuticals

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Monday, May, 9th. The company reported $0.47 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.14. The company had revenue of $120.37 million for the quarter, compared to the consensus estimate of $110.60 million. Amphastar Pharmaceuticals had a net margin of 17.87% and a trailing twelve-month return on equity of 17.35%. During the same period in the previous year, the firm earned $0.27 EPS.
View Amphastar Pharmaceuticals' earnings history

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:
  • Dr. Ziping Luo Ph.D., Chairman, Chief Scientist & COO (Age 72, Pay $1.34M)
  • Dr. Yongfeng Zhang Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 75, Pay $1.93M)
  • Mr. William J. Peters M.B.A., CFO, Exec. VP of Fin. & Treasurer (Age 54, Pay $1.11M) (LinkedIn Profile)
  • Mr. Jacob Liawatidewi M.B.A., Exec. VP of Sales, Marketing & Corp. Admin. Center and Corp. Sec. (Age 48, Pay $773.69k)
  • Mr. Rong Zhou M.S., Exec. VP of Production Center (Age 63, Pay $842.77k) (LinkedIn Profile)
  • Dan Dischner, VP of Corp. Communications
  • Tony Marrs, Sr. VP of Regulatory Affairs and Clinical Operations
  • Mr. Peter Langosh, VP of Operational Improvement and VP of Internal Audit (Age 69)

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $34.15.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.67 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.61 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,761 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for Amphastar Pharmaceuticals is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at [email protected], or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.